周五盘中，基石药业-B（02616）股价大跌6.17%，引发市场关注。这一显著跌幅主要源于公司发布的2025年中期业绩报告。
根据公告，基石药业-B截至2025年6月30日的六个月内，公司录得亏损2.7亿元人民币，相较去年同期1569.9万元人民币的纯利，出现明显的盈转亏。每股亏损达0.21元人民币。更值得注意的是，公司收入同比大幅下降80.5%，仅为4945万元人民币。
分析人士指出，基石药业-B的业绩大幅下滑可能反映了公司在市场竞争和产品销售方面面临的挑战。此外，公司宣布不派发中期股息，这可能进一步打击了投资者信心。市场将密切关注公司未来的战略调整和业绩改善措施。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.